 Bloomberg |
Teva Pursues First Type 1 Diabetes Treatment Since Insulin
BusinessWeek Diamyd Medical AB terminated an agreement with a Johnson & Johnson unit to develop a Type 1 diabetes treatment in June after the medicine failed to preserve beta cell function after 15 months, the primary goal in a late-stage trial. … Teva nearing post-insulin diabetes therapyGlobes Teva looks to revolutionize Type 1 diabetes therapy with Sanofi cast-off …FiercePharma all 7 news articles » |
More details can be found at www.diabeteshowto.com
Discussion
Comments are disallowed for this post.
Comments are closed.